Cited 23 times in
Efficacy of a combined alendronate and calcitriol agent (Maxmarvil?) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박병우 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 송기준 | - |
dc.contributor.author | 이유미 | - |
dc.contributor.author | 임승길 | - |
dc.date.accessioned | 2014-12-18T09:51:42Z | - |
dc.date.available | 2014-12-18T09:51:42Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 0918-8959 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/88967 | - |
dc.description.abstract | The use of aromatase inhibitor (AI) in postmenopausal women with hormone receptor (HR)-positive early breast cancer (EBC) produces a deleterious effect on bone mass and an increase in fractures. Several studies using intravenous bisphosphonates have shown effective management of AI-induced bone loss. To determine whether a lower dosage in oral form combined with calcitriol can effectively manage AI-induced bone loss, we performed a randomized, double-blind, prospective, placebo-controlled 24-week trial with a combination of alendronate and 0.5-µg of calcitriol daily to HR-positive EBC patients. A total of 98 Korean postmenopausal women with HR-positive EBC who received daily AI, calcium and vitamin D were randomly assigned to 5-mg of alendronate and 0.5-µg of calcitriol (Maxmarvil®) or placebo groups. The bone mineral density (BMD) and turnover markers were measured. At week 24, the difference in lumbar BMD between the groups was 3.0% (p < 0.005). The increase in C-telopeptide after 24 weeks was significantly less in the Maxmarvil group compared to that in the placebo group (35.2 ± 17.5% vs. 109.8 ± 28.6%, p < 0.05). Our study demonstrates that a combination of 5-mg alendronate and 0.5-µg calcitriol is effective to prevent bone loss due to AI in Korean postmenopausal women with EBC. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.relation.isPartOf | ENDOCRINE JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Alendronate/administration & dosage | - |
dc.subject.MESH | Alendronate/therapeutic use* | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects* | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use | - |
dc.subject.MESH | Aromatase Inhibitors/adverse effects* | - |
dc.subject.MESH | Aromatase Inhibitors/therapeutic use | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Bone Density/drug effects | - |
dc.subject.MESH | Bone Density Conservation Agents/therapeutic use* | - |
dc.subject.MESH | Bone Resorption/chemically induced | - |
dc.subject.MESH | Bone Resorption/prevention & control* | - |
dc.subject.MESH | Bone and Bones/drug effects | - |
dc.subject.MESH | Bone and Bones/metabolism | - |
dc.subject.MESH | Breast Neoplasms/blood | - |
dc.subject.MESH | Breast Neoplasms/complications | - |
dc.subject.MESH | Breast Neoplasms/drug therapy* | - |
dc.subject.MESH | Breast Neoplasms/metabolism | - |
dc.subject.MESH | Calcitriol/administration & dosage | - |
dc.subject.MESH | Calcitriol/therapeutic use* | - |
dc.subject.MESH | Calcium, Dietary/therapeutic use | - |
dc.subject.MESH | Cholecalciferol/therapeutic use | - |
dc.subject.MESH | Collagen Type I/blood | - |
dc.subject.MESH | Collagen Type I/metabolism | - |
dc.subject.MESH | Combined Modality Therapy | - |
dc.subject.MESH | Dietary Supplements | - |
dc.subject.MESH | Double-Blind Method | - |
dc.subject.MESH | Drug Combinations | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Osteoporosis, Postmenopausal/complications | - |
dc.subject.MESH | Osteoporosis, Postmenopausal/diet therapy | - |
dc.subject.MESH | Osteoporosis, Postmenopausal/drug therapy* | - |
dc.subject.MESH | Patient Dropouts | - |
dc.subject.MESH | Peptides/blood | - |
dc.subject.MESH | Peptides/metabolism | - |
dc.subject.MESH | Postmenopause | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Efficacy of a combined alendronate and calcitriol agent (Maxmarvil?) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: a double-blind, randomized, placebo-controlled study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yumie Rhee | - |
dc.contributor.googleauthor | Kijun Song | - |
dc.contributor.googleauthor | Seho Park | - |
dc.contributor.googleauthor | Hyung Seok Park | - |
dc.contributor.googleauthor | Sung-Kil Lim | - |
dc.contributor.googleauthor | Byeong Woo Park | - |
dc.identifier.doi | 10.1507/endocrj.EJ12-0283 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A02016 | - |
dc.contributor.localId | A03012 | - |
dc.contributor.localId | A03375 | - |
dc.relation.journalcode | J00769 | - |
dc.identifier.eissn | 1348-4540 | - |
dc.identifier.pmid | 23064476 | - |
dc.subject.keyword | Aromatse inhibitor | - |
dc.subject.keyword | Alendronate | - |
dc.subject.keyword | Calcitriol | - |
dc.subject.keyword | Combinative agent | - |
dc.subject.keyword | Osteoporosis | - |
dc.contributor.alternativeName | Park, Byeong Woo | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.alternativeName | Park, Hyung Seok | - |
dc.contributor.alternativeName | Song, Ki Jun | - |
dc.contributor.alternativeName | Rhee, Yumie | - |
dc.contributor.alternativeName | Lim, Sung Kil | - |
dc.contributor.affiliatedAuthor | Park, Byeong Woo | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Park, Hyung Seok | - |
dc.contributor.affiliatedAuthor | Song, Ki Jun | - |
dc.contributor.affiliatedAuthor | Rhee, Yumie | - |
dc.contributor.affiliatedAuthor | Lim, Sung Kil | - |
dc.rights.accessRights | not available | - |
dc.citation.volume | 60 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 167 | - |
dc.citation.endPage | 172 | - |
dc.identifier.bibliographicCitation | ENDOCRINE JOURNAL, Vol.60(2) : 167-172, 2013 | - |
dc.identifier.rimsid | 33709 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.